134 related articles for article (PubMed ID: 32487627)
21. The use of trastuzumab in New Zealand women with breast cancer.
Lawrenson R; Lao C; Campbell I; Harvey V; Brown C; Seneviratne S; Edwards M; Elwood M; Kuper-Hommel M
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e152-e160. PubMed ID: 28856817
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients.
Li S; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
BMC Cancer; 2021 Jul; 21(1):807. PubMed ID: 34256710
[TBL] [Abstract][Full Text] [Related]
23. Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials.
Niraula S; Gyawali B
Breast Cancer Res Treat; 2019 Jan; 173(1):103-109. PubMed ID: 30238273
[TBL] [Abstract][Full Text] [Related]
24. Is trastuzumab as a single agent obsolete in early breast cancer? No.
Bianchini G
Breast; 2019 Feb; 43():142-145. PubMed ID: 30578129
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
Chen S; Liang Y; Feng Z; Wang M
BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
[TBL] [Abstract][Full Text] [Related]
27. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
de Nonneville A; Gonçalves A; Zemmour C; Classe JM; Cohen M; Lambaudie E; Reyal F; Scherer C; Muracciole X; Colombo PE; Giard S; Rouzier R; Villet R; Chopin N; Darai E; Garbay JR; Gimbergues P; Sabiani L; Coutant C; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Breast Cancer Res Treat; 2017 Apr; 162(2):307-316. PubMed ID: 28155054
[TBL] [Abstract][Full Text] [Related]
28. Resumption of Trastuzumab in Patients With Disease Recurrence After (Neo-) Adjuvant Anti-HER2-therapy in Patients With HER2-positive Breast Cancer.
Hanker LC; FÖrster F; SchrÖder J; Grafe A; Hitschold T; Hesse T; Lattrich CR; Rody A
Anticancer Res; 2020 Jul; 40(7):3973-3981. PubMed ID: 32620640
[TBL] [Abstract][Full Text] [Related]
29. [Real-life study of 7-year survival in patients treated with trastuzumab for HER2+ early breast cancer].
Saghatchian M; Curtit E; Coeffic D; Flinois A; Levy C
Bull Cancer; 2020; 107(7-8):745-755. PubMed ID: 32532419
[TBL] [Abstract][Full Text] [Related]
30. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
[TBL] [Abstract][Full Text] [Related]
31. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
[TBL] [Abstract][Full Text] [Related]
32. A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study.
Kubo M; Kawai M; Kumamaru H; Miyata H; Tamura K; Yoshida M; Ogo E; Nagahashi M; Asaga S; Kojima Y; Kadoya T; Aogi K; Niikura N; Miyashita M; Iijima K; Hayashi N; Yamamoto Y; Imoto S; Jinno H
Breast Cancer Res Treat; 2019 Dec; 178(3):647-656. PubMed ID: 31451979
[TBL] [Abstract][Full Text] [Related]
33. Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).
Daniels B; Kiely BE; Houssami N; Lord SJ; Dobbins T; Lu CY; Ward RL; Pearson SA
Br J Cancer; 2018 Feb; 118(3):441-447. PubMed ID: 29136405
[TBL] [Abstract][Full Text] [Related]
34. Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients.
Mustacchi G; Puglisi F; Molino AM; Crivellari D; Ghiotto C; Ferro A; Brunello A; Saracchini S; Turazza M; Cretella E; Iop A; Malagoli M; Stefani M
Future Oncol; 2015; 11(10):1493-500. PubMed ID: 25708426
[TBL] [Abstract][Full Text] [Related]
35. Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment?
Tognela A; Beith J; Kiely B; Bastick P; Lynch J; Descallar J; Mok K
Clin Breast Cancer; 2015 Aug; 15(4):277-84. PubMed ID: 25676930
[TBL] [Abstract][Full Text] [Related]
36. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
37. Systemic therapy for HER2-positive early-stage breast cancer.
Mathew A; Romond EH
Curr Probl Cancer; 2016; 40(2-4):106-116. PubMed ID: 27816189
[TBL] [Abstract][Full Text] [Related]
38. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis.
Shen Y; Fujii T; Ueno NT; Tripathy D; Fu N; Zhou H; Ning J; Xiao L
Breast Cancer Res Treat; 2019 Jan; 173(1):1-9. PubMed ID: 30242579
[TBL] [Abstract][Full Text] [Related]
40. Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
Gullo G; Walsh N; Fennelly D; Bose R; Walshe J; Tryfonopoulos D; O'Mahony K; Hammond L; Silva N; McDonnell D; Ballot J; Quinn C; McDermott EW; Evoy D; Prichard R; Geraghty J; Amstrong J; Crown J
Br J Cancer; 2018 Aug; 119(3):374-380. PubMed ID: 29773838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]